Aptorum Group (APM) Competitors $1.10 -0.01 (-1.34%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$1.10 0.00 (-0.01%) As of 02/21/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends APM vs. TENX, CGTX, FNCH, DRRX, CARA, CTXR, TRAW, ENLV, BCAB, and TNXPShould you be buying Aptorum Group stock or one of its competitors? The main competitors of Aptorum Group include Tenax Therapeutics (TENX), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), DURECT (DRRX), Cara Therapeutics (CARA), Citius Pharmaceuticals (CTXR), Traws Pharma (TRAW), Enlivex Therapeutics (ENLV), BioAtla (BCAB), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. Aptorum Group vs. Tenax Therapeutics Cognition Therapeutics Finch Therapeutics Group DURECT Cara Therapeutics Citius Pharmaceuticals Traws Pharma Enlivex Therapeutics BioAtla Tonix Pharmaceuticals Aptorum Group (NASDAQ:APM) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do analysts prefer APM or TENX? Tenax Therapeutics has a consensus price target of $16.00, indicating a potential upside of 137.04%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Aptorum Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation and earnings, APM or TENX? Aptorum Group has higher revenue and earnings than Tenax Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptorum Group$430K13.19-$2.83MN/AN/ATenax TherapeuticsN/AN/A-$7.71MN/AN/A Which has more volatility & risk, APM or TENX? Aptorum Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Is APM or TENX more profitable? Aptorum Group's return on equity of 0.00% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptorum GroupN/A N/A N/A Tenax Therapeutics N/A -46.00%-42.65% Does the MarketBeat Community believe in APM or TENX? Tenax Therapeutics received 103 more outperform votes than Aptorum Group when rated by MarketBeat users. However, 68.33% of users gave Aptorum Group an outperform vote while only 56.03% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformAptorum GroupOutperform Votes4168.33% Underperform Votes1931.67% Tenax TherapeuticsOutperform Votes14456.03% Underperform Votes11343.97% Does the media refer more to APM or TENX? In the previous week, Tenax Therapeutics had 1 more articles in the media than Aptorum Group. MarketBeat recorded 1 mentions for Tenax Therapeutics and 0 mentions for Aptorum Group. Aptorum Group's average media sentiment score of 0.00 equaled Tenax Therapeutics'average media sentiment score. Company Overall Sentiment Aptorum Group Neutral Tenax Therapeutics Neutral Do institutionals & insiders hold more shares of APM or TENX? 3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryAptorum Group and Tenax Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Aptorum Group News Delivered to You Automatically Sign up to receive the latest news and ratings for APM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APM vs. The Competition Export to ExcelMetricAptorum GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.75M$7.06B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.7326.0419.11Price / Sales13.19306.03447.4676.36Price / CashN/A65.6738.0134.83Price / Book0.376.717.644.62Net Income-$2.83M$138.33M$3.18B$245.85M7 Day Performance-7.97%-2.63%-2.00%-2.61%1 Month Performance-2.22%-2.33%-0.44%-2.14%1 Year Performance-36.33%-5.33%16.44%12.98% Aptorum Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APMAptorum Group0.5007 of 5 stars$1.10-1.3%N/A-38.1%$5.75M$430,000.000.0030Gap UpTENXTenax Therapeutics1.9285 of 5 stars$7.20-1.4%$16.00+122.2%+55.2%$24.55MN/A0.009News CoverageGap UpCGTXCognition Therapeutics3.3333 of 5 stars$0.59+0.0%$8.30+1,306.5%-70.7%$24.52MN/A-0.6120News CoverageFNCHFinch Therapeutics GroupN/A$15.00-3.2%N/A+537.1%$24.09M$110,000.00-1.70190News CoverageHigh Trading VolumeDRRXDURECT3.3392 of 5 stars$0.77+2.5%$5.00+550.2%-10.9%$23.87M$8.55M-1.2680News CoverageCARACara Therapeutics3.7675 of 5 stars$5.20-7.1%$27.84+435.4%-38.8%$23.76M$20.97M-0.2580News CoverageCTXRCitius Pharmaceuticals3.0704 of 5 stars$2.69-0.4%$54.50+1,926.0%-90.6%$23.11MN/A-0.4520Earnings ReportAnalyst ForecastNews CoverageGap UpTRAWTraws Pharma0.5212 of 5 stars$6.21-7.3%N/AN/A$22.67M$230,000.00-0.0417News CoverageGap DownENLVEnlivex Therapeutics3.0716 of 5 stars$1.05+1.0%$9.50+804.8%-68.9%$22.48MN/A-1.0770BCABBioAtla2.7082 of 5 stars$0.46+6.6%$6.00+1,191.4%-83.1%$22.46MN/A-0.2760High Trading VolumeTNXPTonix Pharmaceuticals3.2463 of 5 stars$11.95+4.5%$5,350.00+44,669.9%-99.2%$22.35M$7.77M0.0050Gap Up Related Companies and Tools Related Companies TENX Competitors CGTX Competitors FNCH Competitors DRRX Competitors CARA Competitors CTXR Competitors TRAW Competitors ENLV Competitors BCAB Competitors TNXP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APM Stock Alerts